In vivo we found, for the first time that knocking out CD44, specifically in mesenchymal cells, excluding the hematopoietic lineage, leads to significantly improved outcome in the regenerative capacity of the tissue following bleomycin injury, particularly reducing EMT (Figure 4) and pulmonary fibrosis (Figure 5). Here, CD44 is linked to pulmonary fibrosis.